Your browser doesn't support javascript.

Portal Regional da BVS

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis.

Ann Pharmacother; : 1060028018799982, 2018 Sep 06.
Artigo em Inglês | MEDLINE | ID: mdl-30187769


To review the efficacy, safety, and place in therapy of ixekizumab for the treatment of moderate to severe plaque psoriasis.DATA SOURCES: PubMed (1966 to July 2018) and were searched using the terms ixekizumab, LY2439821, interleukin-17, and psoriasis. STUDY SELECTION AND DATA EXTRACTION: Human studies published in peer-reviewed medical journals in English were used.


The efficacy and safety of ixekizumab has been primarily reported by 4 phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3, and UNCOVER-J) and multiple post hoc analyses. The average proportions of patients achieving a 75%, 90%, and 100% reduction in their Psoriasis Area and Severity Index (PASI) were 89%, 70%, and 38%, respectively, after 12 weeks of therapy. PASI75 was maintained for up to 3 years in 80.5% of participants. Ixekizumab was statistically significantly more effective than ustekinumab, with 76.5%, compared with 59%, of patients achieving PASI90 in 52 weeks. The most common adverse events include nasopharyngitis (14.1%), upper respiratory tract infections (7.9%), and injection-site reactions (6.8%), which are similar to that for other biological agents. The risk of inflammatory bowel disease may be increased with ixekizumab. Relevance to Patient Care and Clinical Practice: This review summarizes and evaluates clinical data regarding the efficacy and safety of ixekizumab and discusses relevant differences compared with other biological agents used for the management of chronic plaque psoriasis.


Ixekizumab is a highly efficacious and well-tolerated treatment option for patients with moderate to severe plaque psoriasis.